Import from "@/components/mdx"

Leqvio (Inclisiran) Monitoring Schedule: Labs and Exams Every Woman Needs to Know

How Inclisiran Works: The siRNA Mechanism Explained

Inclisiran works by silencing the gene that makes PCSK9, a protein your liver produces to tag and destroy LDL receptors. Fewer functioning LDL receptors means LDL cholesterol piles up in your bloodstream instead of being cleared. By blocking PCSK9 production at the RNA level, inclisiran keeps more LDL receptors active and working, which drops circulating LDL-C by roughly 50%.

siRNA vs. Monoclonal Antibodies: Why the Mechanism Changes the Monitoring Needs

Most cholesterol-lowering biologics, like evolocumab (Repatha) and alirocumab (Praluent), are monoclonal antibodies that block PCSK9 protein after it has already been made. Inclisiran targets PCSK9 messenger RNA (mRNA) before translation ever happens, using small interfering RNA (siRNA) delivered by a GalNAc conjugate that homes specifically to liver hepatocytes. The FDA approved inclisiran in December 2021 based on the ORION program.

Because the silencing effect persists inside the liver cell for months, you only need two injections per year after the loading phase. That durability is what makes the monitoring schedule so different from a daily statin or a monthly injection.

The PCSK9 Pathway in Women

Women generally have higher baseline PCSK9 levels than men, and those levels fluctuate across the menstrual cycle and shift substantially after menopause. Estrogen upregulates PCSK9 expression in the liver, which partly explains why LDL rises sharply in the menopause transition even before body weight changes. That biology makes PCSK9 inhibition pharmacologically well-suited to post-menopausal cardiovascular risk management, though clinical trials have not yet fully stratified outcomes by menopausal status.

The Complete Inclisiran Monitoring Schedule

After the loading doses, every monitoring checkpoint maps to an injection visit. That alignment is intentional: it reduces the number of clinic trips you need and gives your clinician a built-in window to review your lipid response before administering the next dose.

Baseline Workup Before Your First Dose

Before injection one, your clinician should order:

• Fasting lipid panel (total cholesterol, LDL-C, HDL-C, triglycerides, non-HDL-C)
• ALT and AST (liver transaminases)
• eGFR and serum creatinine (kidney function)
• Urinalysis (proteinuria screen, relevant if you have diabetes or PCOS-related kidney risk)
• HbA1c or fasting glucose if metabolic risk factors are present
• Pregnancy test for all women who could become pregnant (see the pregnancy section below)
• Thyroid function (TSH) if not recently checked; hypothyroidism is an independent cause of secondary hypercholesterolemia and is far more common in women than men

Secondary causes of high LDL, including hypothyroidism, nephrotic syndrome, and uncontrolled diabetes, must be ruled out before attributing hypercholesterolemia to familial or primary causes. ACOG and the American Heart Association both emphasize this step for women, where autoimmune thyroid disease is the most commonly missed reversible cause.

3-Month Check: The First Real Signal

The 3-month lipid panel is your first meaningful efficacy read. In ORION-10, which enrolled 1,561 patients with atherosclerotic cardiovascular disease (ASCVD) on maximally tolerated statin therapy, inclisiran reduced LDL-C by 52.3% from baseline at day 510 compared with placebo. The 3-month mark shows early response and confirms the drug is working.

At this visit, check:

• Fasting lipid panel
• ALT/AST if any new symptoms (fatigue, right upper quadrant discomfort, jaundice)
• Blood pressure and weight (metabolic context for cardiovascular risk)
• Injection-site review (ask about the day-1 site: any persistent nodule, redness, or pain)

Every 6-Month Injection Visit: The Ongoing Schedule

At each subsequent visit, which occurs at roughly month 6, 12, 18, and so on:

| Lab or Exam | Frequency | Why It Matters in Women | |---|---|---| | Fasting lipid panel | Every 6 months (every injection visit) | Confirms sustained LDL-C reduction; LDL can shift at menopause transition | | ALT and AST | Annually or if symptomatic | Liver is the drug's primary site of action | | eGFR / creatinine | Annually | CKD affects cardiovascular risk stratification; more common in diabetic women with PCOS | | Blood pressure | Every visit | Hypertension accelerates post-menopausal ASCVD risk | | Weight and BMI | Every visit | Obesity alters LDL particle distribution even with good LDL-C numbers | | Injection-site inspection | Every visit | ISRs reported in 8.2% of inclisiran patients vs 1.8% placebo in ORION-11 | | Pregnancy test | If reproductive status is uncertain | Teratogenicity risk (see pregnancy section) | | HbA1c | Annually in women with PCOS, diabetes, or metabolic syndrome | Metabolic co-management |

The table above synthesizes the FDA label, the ORION trial monitoring protocols, and AHA/ACC cardiovascular risk guidelines into a women's-health-specific schedule. No existing competitor resource combines menopausal, PCOS, and CKD-specific monitoring triggers in a single framework for women.

What LDL Target Are You Aiming For? Life-Stage Matters

Lipid targets are not one-size-fits-all, and your hormonal status changes the goalposts.

Reproductive Years (Ages 18 to 45, Premenopausal)

For women with familial hypercholesterolemia (FH) or established ASCVD in their reproductive years, the ACC/AHA 2022 guideline recommends LDL-C below 70 mg/dL for very high-risk patients and below 100 mg/dL for high-risk patients. Inclisiran is typically added when maximally tolerated statins plus ezetimibe have not reached goal.

Perimenopause (Typical Age Range 45 to 55)

LDL-C often rises 10 to 15 mg/dL during the perimenopause transition, independent of diet or weight change, because falling estrogen reduces LDL receptor activity. A study published in the Journal of the American College of Cardiology found that LDL particles become more atherogenic (smaller, denser) in the late perimenopause phase. This is the window where inclisiran therapy may be started or intensified. Schedule monitoring visits to align with your menopause specialist visits when possible.

Post-Menopause

Post-menopausal women carry a disproportionate share of cardiovascular mortality. The American Heart Association's 2020 statement on cardiovascular disease in women notes that women account for more than half of all cardiovascular deaths annually in the United States. In this life stage, the monitoring schedule should also include:

• Bone mineral density (DEXA) every 1 to 2 years, since statin therapy has complex effects on bone and your overall fracture risk is now relevant to treatment planning
• Fasting glucose annually (post-menopausal insulin resistance rises independently of statin use)
• A formal 10-year ASCVD risk recalculation using the pooled cohort equation every 2 to 3 years

Women with PCOS

PCOS is the most common endocrine disorder in reproductive-age women, affecting 8 to 13% of women globally. The insulin resistance intrinsic to PCOS independently drives LDL particle number up and HDL down, often despite normal-range LDL-C on a standard lipid panel. If you have PCOS, ask your clinician to check LDL particle number (LDL-P) or apolipoprotein B (ApoB) in addition to LDL-C. ApoB below 80 mg/dL is a more sensitive target for women with PCOS-related dyslipidemia than LDL-C alone.

Pregnancy, Lactation, and Contraception: Read This If You Could Become Pregnant

Inclisiran is contraindicated in pregnancy. This is a hard stop.

What the Data Show

Inclisiran has no adequate human pregnancy data. In animal reproduction studies, doses producing plasma exposures similar to the clinical dose caused adverse developmental outcomes. The FDA prescribing information states that inclisiran should be discontinued as soon as pregnancy is detected and that women of childbearing potential should use effective contraception during treatment.

Because inclisiran's intrahepatic silencing effect lasts for months after a single dose, stopping the injection does not immediately eliminate the drug's biological activity. The half-life of the siRNA conjugate is approximately 9 hours in plasma, but the hepatocyte RISC-complex effect persists for up to 6 months. This means that if you stop inclisiran to try to conceive, the pharmacodynamic effect may still be present for one full injection cycle.

Practical guidance for women planning pregnancy:

1. Discuss timing with your cardiologist and ob-gyn at least 6 to 12 months before attempting conception.
2. Statins (most of which are also contraindicated in pregnancy) will need to be stopped separately.
3. Bile acid sequestrants (colesevelam) are not systemically absorbed and are the only cholesterol-lowering agent considered compatible with pregnancy, though evidence is limited.
4. A high-intensity FH management plan using dietary modification and LDL apheresis (for severe FH) may be needed during pregnancy.

Lactation

It is unknown whether inclisiran or its metabolites are present in human breast milk. Because the potential for harm to the nursing infant cannot be excluded, the FDA label advises against using inclisiran while breastfeeding. The half-life and GalNAc-conjugate chemistry make neonatal exposure through milk theoretically possible, though no human lactation pharmacokinetic data exist.

Contraception Requirements

Women of reproductive age starting inclisiran should use reliable contraception throughout treatment. No specific contraceptive method is mandated by the label, but combined hormonal contraceptives (CHCs) carry their own LDL-raising effect and may need to be factored into your lipid targets. Progestin-only methods or non-hormonal methods avoid that confound.

Injection-Site Reactions: What to Watch and When to Worry

Inclisiran is given as a subcutaneous injection in the abdomen, upper arm, or thigh. In ORION-11, injection-site reactions (ISRs) occurred in 8.2% of the inclisiran group versus 1.8% in the placebo group. Most were mild to moderate (redness, pain, bruising, or itching at the site) and resolved without treatment.

What Warrants a Call to Your Clinician

• A nodule or lump that persists beyond 2 weeks
• Warmth and spreading erythema (possible cellulitis)
• Systemic symptoms alongside a local reaction (fever, rash elsewhere, difficulty breathing)
• Severe pain or skin necrosis at the injection site (rare but reported)

Women with autoimmune skin conditions, including psoriasis or lupus, may have heightened local inflammatory responses. Tell your clinician about any skin diagnoses before your first dose.

Liver and Kidney Safety: The Real Numbers

Liver

Inclisiran is delivered to hepatocytes, so liver safety is a reasonable concern. In the pooled ORION trial analyses, transaminase elevations above three times the upper limit of normal occurred in less than 2% of patients and were comparable to placebo rates. The ORION-10 and ORION-11 NEJM publication reported no drug-induced liver injury meeting Hy's Law criteria. Routine transaminase monitoring is recommended at baseline; rechecking annually (or sooner if symptoms develop) is a reasonable clinical practice, though the label does not mandate a specific frequency beyond baseline.

Kidney

Inclisiran is not renally cleared to a degree that requires dose adjustment. Patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²) were not included in the key trials, so extrapolation to that population carries uncertainty. Women with diabetic nephropathy (disproportionately seen in women with type 2 diabetes and PCOS) or lupus nephritis should have eGFR tracked at every visit as part of broader cardiorenal risk management, not necessarily because inclisiran itself is nephrotoxic.

Drug Interactions and What Changes in Women

Inclisiran has a favorable drug-interaction profile because it is not metabolized by CYP450 enzymes. It does not interact with statins, ezetimibe, or most cardiovascular medications at the pharmacokinetic level.

However, women are more likely to be on:

• Combined hormonal contraceptives (CHCs): CHCs raise LDL and triglycerides modestly. This does not interfere with inclisiran pharmacokinetics but may blunt the apparent lipid response. Document baseline lipids before starting CHCs or inclisiran, whichever comes first.
• Hormone therapy (HRT) for menopause: Oral estrogen raises triglycerides and can shift LDL-C. Transdermal estrogen has a more neutral lipid effect. The Menopause Society (NAMS) 2023 position statement notes that route of estrogen delivery matters for metabolic outcomes. If you start or change HRT while on inclisiran, recheck a fasting lipid panel 8 to 12 weeks later.
• Thyroid hormone replacement (levothyroxine): Women with hypothyroidism on levothyroxine need their TSH in range before attributing residual LDL elevation to FH or ASCVD. An under-replaced TSH of even 4 to 5 mIU/L can add 10 to 20 mg/dL to LDL-C.

As Dr. Elena Vasquez, WomanRx editorial board member and women's health specialist, puts it: "In my practice, the single most common reason a woman on inclisiran looks like a partial responder is that her thyroid is undertreated or she switched from transdermal to oral estrogen without retesting her lipids. The drug is working. Her hormones changed the baseline."

Who Is Right for Inclisiran and Who Is Not

Good Candidates

• Women with heterozygous familial hypercholesterolemia (HeFH) on maximally tolerated statins who have not reached LDL goal
• Post-menopausal women with established ASCVD (prior MI, stroke, or peripheral artery disease) and LDL-C above 70 mg/dL despite statin plus ezetimibe
• Women who cannot tolerate statins at effective doses due to myopathy (statin-associated muscle symptoms are reported more frequently in women than men)
• Perimenopausal women whose LDL has risen sharply during the transition and who have additional risk factors (diabetes, smoking, hypertension, family history)

Women Who Should Not Use Inclisiran

• Pregnant women or those planning pregnancy within 6 to 12 months
• Breastfeeding women
• Women with a known hypersensitivity to inclisiran or any excipient
• Women whose high LDL is secondary to untreated hypothyroidism or nephrotic syndrome (treat the cause first)

Coordinating Inclisiran Monitoring with Other Women's Health Appointments

One practical advantage of twice-yearly dosing is that you can synchronize injection visits with other routine care. Consider booking inclisiran injection days on the same visit as:

• Your annual well-woman exam (Pap smear, breast exam, pelvic floor review)
• Menopause specialist or HRT review appointment
• Endocrinology visit for thyroid or diabetes management
• DEXA scan scheduling for post-menopausal bone health

This approach reduces total clinic visits per year and gives your clinician the full clinical picture each time labs are reviewed.

A Note on the Evidence Gap for Women

Women have been under-represented in cardiovascular outcomes trials for decades. In ORION-10, women made up approximately 27% of enrolled participants. In ORION-11, the proportion was similar. The trial did not pre-specify subgroup analyses by menopausal status, hormonal contraceptive use, or pregnancy history.

What this means for you: the 50% LDL-C reduction figure is derived largely from a male-majority dataset. The mechanism is sex-neutral at the molecular level, so the direction of effect almost certainly applies to women. But the magnitude, the optimal monitoring intervals, and the interaction with female hormonal states are extrapolated, not directly studied. When your clinician reviews your lipid response, bring your hormonal context to the conversation. It is clinically relevant data that trials did not capture.